Renovos, based on over a decade of world-class stem cell research at the University of Southampton, is transforming orthopaedics and regenerative medicine through pioneering use of nanoclay gels to deliver, retain and safely release biologics. Renovos’ proprietary formulations, Renovite®, are easy to handle, form a biodegradable gel after injection and can deliver ultra-low doses of biologics versus other formulations with the same efficacy. The Renovite® platform retains active agents and releases them only to target cells interacting with the nanoclay. Renovos’ mission is to unlock the full potential of regenerative medicine with the innovative Renovite® technology platform, and help clinicians deliver safe and more efficacious treatments for tissue repair. With a granted patent and a strong scientific and commercial team, the company is progressing through development of its proprietary delivery platform, as well as offering the wider research community at universities, biotech and pharma high-value human stem cells and disruptive new assay platforms to generate the next generation of medicines, combating the global ageing population.